

SenzaGen secures SEK 1.7m order from a new global biotech industry leader

Lund, December 18, 2023

SenzaGen has been selected to test substances for yet another new global customer within the biotech industry. The assignment is valued at SEK 1.7 million and includes non-animal tests for skin sensitization, utilizing SenzaGen's highly performing test platform, GARD@skin. The tests will be conducted at the company's GLP-certified laboratories in Lund and at the subsidiary, VitroScreen, in Milan during the fourth quarter of 2023 and the first quarter of 2024.

The customer is a global leader in biotech with a significant presence and research in various chemical areas. Through this testing, they aim to investigate whether their new product candidates can cause allergic reactions on the skin.

"Through this order, we further broaden our portfolio with another world player choosing us to replace animal experiments with more ethical methods. The acquisition of VitroScreen has strengthened our position in skin sensitization and now opens up new opportunities in the market. With our combined product portfolio, we offer our customers a comprehensive testing solution, providing them with fast and reliable test results for evaluating product candidates," says Peter Nählstedt, President and CEO of SenzaGen.

The core of SenzaGen's business revolves around innovative tests and services within non-animal toxicology and efficacy testing. These innovations are based on the company's extensive expertise in various technology areas, including genomics, machine learning, and human 3D tissue models. By offering unique and groundbreaking innovations that are better suited to reflect human biological reactions, SenzaGen is driving progress away from animal testing.

Contacts

Peter Nählstedt, President and CEO, SenzaGen AB

Email: peter.nahlstedt@senzagen.com | Mobile: +46 700 23 44 31

Tina Dackemark Lawesson, VP Marketing & Communications

Email: tina.lawesson@senzagen.com | Mobile: +46 708 20 29 44



About us

SenzaGen is a corporate group that aims to be a leader in *in vitro* science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® and VitroScreen ORA® test platforms, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company's Certified Adviser.

Attachments

[SenzaGen secures SEK 1.7m order from a new global biotech industry leader](#)